Literature DB >> 10825165

Conditional expression of RNA polymerase II in mammalian cells. Deletion of the carboxyl-terminal domain of the large subunit affects early steps in transcription.

M Meininghaus1, R D Chapman, M Horndasch, D Eick.   

Abstract

The carboxyl-terminal domain (CTD) of the large subunit of mammalian RNA polymerase II contains 52 repeats of a heptapeptide that is the target of a variety of kinases. The hyperphosphorylated CTD recruits important factors for mRNA capping, splicing, and 3'-processing. The role of the CTD for the transcription process in vivo, however, is not yet clear. We have conditionally expressed an alpha-amanitin-resistant large subunit with an almost entirely deleted CTD (LS*Delta5) in B-cells. These cells have a defect in global transcription of cellular genes in the presence of alpha-amanitin. Moreover, pol II harboring LS*Delta5 failed to transcribe up to the promoter-proximal pause sites in the hsp70A and c-fos gene promoters. The results indicate that the CTD is already required for steps that occur before promoter-proximal pausing and maturation of mRNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825165     DOI: 10.1074/jbc.M001883200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes.

Authors:  Ran Taube; Xin Lin; Dan Irwin; Koh Fujinaga; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

2.  Global analysis of stress-regulated mRNA turnover by using cDNA arrays.

Authors:  Jinshui Fan; Xiaoling Yang; Wengong Wang; William H Wood; Kevin G Becker; Myriam Gorospe
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

3.  Prolonged α-amanitin treatment of cells for studying mutated polymerases causes degradation of DSIF160 and other proteins.

Authors:  David C Tsao; Noh Jin Park; Anita Nag; Harold G Martinson
Journal:  RNA       Date:  2011-12-22       Impact factor: 4.942

4.  TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription.

Authors:  Marta Montes; Alexandre Cloutier; Noemí Sánchez-Hernández; Laetitia Michelle; Bruno Lemieux; Marco Blanchette; Cristina Hernández-Munain; Benoit Chabot; Carlos Suñé
Journal:  Mol Cell Biol       Date:  2011-12-12       Impact factor: 4.272

5.  Genetic organization, length conservation, and evolution of RNA polymerase II carboxyl-terminal domain.

Authors:  Pengda Liu; John M Kenney; John W Stiller; Arno L Greenleaf
Journal:  Mol Biol Evol       Date:  2010-06-17       Impact factor: 16.240

6.  Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation.

Authors:  Joanna Y Ip; Dominic Schmidt; Qun Pan; Arun K Ramani; Andrew G Fraser; Duncan T Odom; Benjamin J Blencowe
Journal:  Genome Res       Date:  2010-12-16       Impact factor: 9.043

7.  Role of the mammalian RNA polymerase II C-terminal domain (CTD) nonconsensus repeats in CTD stability and cell proliferation.

Authors:  Rob D Chapman; Marcus Conrad; Dirk Eick
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

8.  Gene-Specific Control of tRNA Expression by RNA Polymerase II.

Authors:  Alan Gerber; Keiichi Ito; Chi-Shuen Chu; Robert G Roeder
Journal:  Mol Cell       Date:  2020-04-15       Impact factor: 17.970

9.  The C-terminal domain of pol II and a DRB-sensitive kinase are required for 3' processing of U2 snRNA.

Authors:  Joanne E Medlin; Patricia Uguen; Alice Taylor; David L Bentley; Shona Murphy
Journal:  EMBO J       Date:  2003-02-17       Impact factor: 11.598

10.  An unusual recent expansion of the C-terminal domain of RNA polymerase II in primate malaria parasites features a motif otherwise found only in mammalian polymerases.

Authors:  Sandeep P Kishore; Susan L Perkins; Thomas J Templeton; Kirk W Deitsch
Journal:  J Mol Evol       Date:  2009-05-16       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.